Genscript Biotech Statistics

Total Valuation

Genscript Biotech has a market cap or net worth of HKD 27.25 billion. The enterprise value is 25.06 billion.

Market Cap	27.25B
Enterprise Value	25.06B

Important Dates

The next estimated earnings date is Friday, November 8, 2024.

Earnings Date	Nov 8, 2024
Ex-Dividend Date	n/a

Share Statistics

Genscript Biotech has 2.13 billion shares outstanding. The number of shares has increased by 0.43% in one year.

Shares Outstanding	2.13B
Shares Change (YoY)	+0.43%
Shares Change (QoQ)	+0.22%
Owned by Insiders (%)	0.20%
Owned by Institutions (%)	18.01%
Float	1.16B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.43
PB Ratio	2.87
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-18.13
EV / Sales	3.18
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-11.75

Financial Position

The company has a current ratio of 4.15, with a Debt / Equity ratio of 0.54.

Current Ratio	4.15
Quick Ratio	3.97
Debt / Equity	0.54
Debt / EBITDA	n/a
Debt / FCF	-3.62
Interest Coverage	-11.75

Financial Efficiency

Return on equity (ROE) is -16.62% and return on invested capital (ROIC) is -7.44%.

Return on Equity (ROE)	-16.62%
Return on Assets (ROA)	-6.40%
Return on Capital (ROIC)	-7.44%
Revenue Per Employee	1.08M
Profits Per Employee	-189,751
Employee Count	6,937
Asset Turnover	0.30
Inventory Turnover	9.15

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -38.16% in the last 52 weeks. The beta is 1.05, so Genscript Biotech's price volatility has been similar to the market average.

Beta (5Y)	1.05
52-Week Price Change	-38.16%
50-Day Moving Average	12.29
200-Day Moving Average	12.86
Relative Strength Index (RSI)	51.55
Average Volume (20 Days)	17,969,171

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genscript Biotech had revenue of HKD 7.88 billion and -1.38 billion in losses. Loss per share was -0.65.

Revenue	7.88B
Gross Profit	4.23B
Operating Income	-2.69B
Pretax Income	-2.44B
Net Income	-1.38B
EBITDA	-2.20B
EBIT	-2.69B
Loss Per Share	-0.65

Full Income Statement

Balance Sheet

The company has 14.67 billion in cash and 7.72 billion in debt, giving a net cash position of 6.95 billion or 3.26 per share.

Cash & Cash Equivalents	14.67B
Total Debt	7.72B
Net Cash	6.95B
Net Cash Per Share	3.26
Equity (Book Value)	14.24B
Book Value Per Share	4.46
Working Capital	13.13B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -155.29 million and capital expenditures -1.98 billion, giving a free cash flow of -2.13 billion.

Operating Cash Flow	-155.29M
Capital Expenditures	-1.98B
Free Cash Flow	-2.13B
FCF Per Share	-1.00

Full Cash Flow Statement

Margins

Gross margin is 53.63%, with operating and profit margins of -34.07% and -17.53%.

Gross Margin	53.63%
Operating Margin	-34.07%
Pretax Margin	-30.90%
Profit Margin	-17.53%
EBITDA Margin	-27.95%
EBIT Margin	-34.07%
FCF Margin	-27.06%

Dividends & Yields

Genscript Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.43%
Shareholder Yield	-0.43%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Genscript Biotech has an Altman Z-Score of 2.04. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.04
Piotroski F-Score	n/a